Aspira Pathlab Board Meeting on Nov 6 to Approve Q2 FY27 Results

Aspira Pathlab & Diagnostics Ltd has announced a Board of Directors meeting scheduled for November 6, 2026. The primary agenda is to consider and approve the Un-Audited Standalone Financial Results for the second quarter and half-year ended September 30, 2026, along with the Limited Review Report. Additionally, the board will discuss other business matters. In compliance with SEBI regulations, the trading window for designated persons and their immediate relatives will be closed until 48 hours after the financial results are declared. The meeting notice will also be available on the company's website.